KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Astrazeneca (AZN) Non-Current Receivables (2016 - 2025)

Astrazeneca has reported Non-Current Receivables over the past 11 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Non-Current Receivables at $1.3 billion for Q4 2025, up 42.69% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 42.69% YoY), and the annual figure for FY2025 was $1.3 billion, up 42.69%.
  • Non-Current Receivables for Q4 2025 was $1.3 billion at Astrazeneca, up from $930.0 million in the prior quarter.
  • Over the last five years, Non-Current Receivables for AZN hit a ceiling of $1.3 billion in Q4 2025 and a floor of $803.0 million in Q4 2023.
  • Median Non-Current Receivables over the past 5 years was $895.0 million (2021), compared with a mean of $958.0 million.
  • Biggest five-year swings in Non-Current Receivables: dropped 6.7% in 2022 and later soared 42.69% in 2025.
  • Astrazeneca's Non-Current Receivables stood at $895.0 million in 2021, then fell by 6.7% to $835.0 million in 2022, then fell by 3.83% to $803.0 million in 2023, then increased by 15.82% to $930.0 million in 2024, then skyrocketed by 42.69% to $1.3 billion in 2025.
  • The last three reported values for Non-Current Receivables were $1.3 billion (Q4 2025), $930.0 million (Q4 2024), and $803.0 million (Q4 2023) per Business Quant data.